Management strategies for one adverse event from experienced nurse practitioners: Episode 2 скачать в хорошем качестве

Management strategies for one adverse event from experienced nurse practitioners: Episode 2

Nurse practitioners Diana Czel and Courtney Arn review safety data from clinical studies SOLO-1 and PAOLA-1 and discuss strategies for managing a common adverse event in patients receiving LYNPARZA® (olaparib). LYNPARZA is indicated as maintenance monotherapy for BRCAm* advanced ovarian cancer after response to first-line platinum-based chemotherapy; and is indicated as maintenance therapy in combination with bevacizumab for HRD+* advanced ovarian cancer after response to first-line platinum-based chemotherapy. *Select patients for therapy based on an FDA-approved companion diagnostic LYNPARZA is associated with serious and potentially fatal adverse events including Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), pneumonitis, and venous thromboembolism (VTE). Monitor patients for signs and symptoms and discontinue LYNPARZA if MDS/AML or pneumonitis is confirmed. Monitor patients for signs and symptoms of VTE and treat as medically appropriate. LYNPARZA can cause fetal harm. Please see complete Important Safety Information at https://www.lynparzahcp.com/ovarian-c... and complete Prescribing Information, including Medication Guide at https://bit.ly/LYNhcpPI. You may report side effects related to AstraZeneca products. https://us-aereporting.astrazeneca.co...